ArticleJournal of clinical pathways : the foundation of value-based care
Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting.
Article in Journal of clinical pathways : the foundation of value-based care. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Real-world characteristics, treatment patterns, and outcomes of patients with mantle cell lymphoma by line of therapy.Future oncology (London, England) · 2026Article
- Precision Prevention, Diagnostics, and Treatment of Obesity: Pipedream or Reality?Obesity (Silver Spring, Md.) · 2025Review
- Strategies for improving biomarker testing rates in non-small cell lung cancer in north America: a scoping review.Journal of thoracic disease · 2025Review
- Article
- Physician preferences of biomarker testing strategies in newly diagnosed stage IV non-small cell lung cancer patients.Future oncology (London, England) · 2024Article
- Modeling Costs and Life-Years Gained by Population-Wide Next-Generation Sequencing or Single-Gene Testing in Nonsquamous Non-Small-Cell Lung Cancer in the United States.JCO precision oncology · 2023Article
- Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes and Personalized, Precision Care Plans.Journal of clinical medicine · 2022Article
- Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib.Lung cancer (Amsterdam, Netherlands) · 2022Article
- Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists.Cancer medicine · 2022Article
- Article
- Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Advanced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data.Advances in therapy · 2021Article
- Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer.JCO oncology practice · 2021Article
- Evaluating the Impact of Oncology Care Model Reporting Requirements on Biomarker Testing and Treatment.JCO oncology practice · 2020Article
- Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies.Journal of clinical medicine · 2020Review
- A National Assessment of Diagnostic Test Use for Patients with Advanced NSCLC and Factors Influencing Physician Decision-Making.American health & drug benefits · 2020Article
- Biomarker testing for personalized, first-line therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study).Therapeutic advances in medical oncology · 2020Article
- Precision medicine and actionable alterations in lung cancer: A single institution experience.PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Despite clear clinical benefit and guideline recommendations for predictive biomarker testing and subsequent first-line targeted therapy treatment in patients with non-small cell lung cancer (NSCLC), there is evidence that testing has not been widely embraced in the clinical setting. This study uses clinical pathways to understand biomarker testing patterns and ensuing first-line treatment decisions. Data of patients with metastatic NSCLC were analyzed for testing rates and treatment selection at 7 cancer programs using data input by providers into the pathways software. Findings were analyzed by type of provider (community or academic). Among providers using clinical pathways, biomarker testing rates were high and appropriate selection of targeted therapy was observed. Clinical pathways can act as a tool to assist oncology practices to promote testing of key biomarkers and subsequent selection of appropriate therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.